REG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - TAKEDA PHARMACEUTICAL
RNS Number : 7432XMorgan Stanley14 August 2018
FORM 8.5 (EPT/NON-RI)
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN
EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader:
Morgan Stanley MUFG Securities Co., Ltd.
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Takeda Pharmaceutical Company Limited
(c) Name of the party to the offer with which exempt principal trader is connected:
Shire plc
(d) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
13 AUGUST 2018
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES - Shire plc
2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
6,141,188
0.78
11,823,544
1.51
(2) Cash-settled derivatives:
11,476,716
1.46
5,653,508
0.72
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
0
0.00
0
0.00
TOTAL:
17,617,904
2.24
17,477,052
2.23
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
N/A
Details, including nature of the rights concerned and relevant percentages:
N/A
3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchases/sales
Total number of securities
Highest price per unit paid/received
Lowest price per unit paid/received
Ordinary
PURCHASES
1,606,326
4,784.0000 JPY
4,638.0000 JPY
Ordinary
SALES
731,126
4,784.0000 JPY
4,639.0000 JPY
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
Ordinary
CFD
SHORT
1000000
4640.0000 JPY
Ordinary
CFD
LONG
131900
4687.7739 JPY
Ordinary
CFD
LONG
34500
4690.2891 JPY
Ordinary
CFD
SHORT
28000
4688.2392 JPY
Ordinary
CFD
SHORT
13600
4664.5988 JPY
Ordinary
CFD
LONG
12700
4685.7480 JPY
Ordinary
CFD
LONG
12600
4698.4761 JPY
Ordinary
CFD
SHORT
5600
4641.5226 JPY
Ordinary
CFD
SHORT
4800
4692.0000 JPY
Ordinary
CFD
LONG
4800
4698.2916 JPY
Ordinary
CFD
SHORT
4000
4672.5000 JPY
Ordinary
CFD
SHORT
3900
4655.5049 JPY
Ordinary
CFD
SHORT
3100
4664.5988 JPY
Ordinary
CFD
LONG
2600
4642.3765 JPY
Ordinary
CFD
SHORT
1100
4642.8054 JPY
Ordinary
CFD
SHORT
600
4645.1666 JPY
Ordinary
CFD
SHORT
500
4640.0000 JPY
Ordinary
CFD
SHORT
400
4640.0000 JPY
Ordinary
CFD
LONG
300
4653.3333 JPY
Ordinary
CFD
SHORT
300
4643.6666 JPY
Ordinary
CFD
SHORT
200
4640.0000 JPY
Ordinary
CFD
SHORT
100
4680.0000 JPY
Ordinary
CFD
LONG
100
4677.0000 JPY
Ordinary
CFD
SHORT
100
4676.0000 JPY
Ordinary
CFD
LONG
100
4642.0000 JPY
Ordinary
CFD
SHORT
100
4689.0000 JPY
Ordinary
CFD
SHORT
100
4689.0000 JPY
Ordinary
CFD
LONG
100
4650.0000 JPY
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit
N/A
N/A
N/A
N/A
N/A
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
N/A
N/A
N/A
N/A
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
NO
Date of disclosure:
14 AUGUST 2018
Contact name:
Craig Horsley
Telephone number:
+44(141) 245 7736
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDFEOEAPPLFDAPEEF
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement